SYSTEMATIC REVIEW

Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review

Bhavna Gupta¹⁰, Pallavi Ahluwalia²⁰, Nidhi Gupta³⁰, Anish Gupta⁴⁰

Received on: 01 May 2023; Accepted on: 14 July 2023; Published on: 31 July 2023

ABSTRACT

Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of this systematic review is to assess the efficacy of nebulized heparin in COVID-19 patients with respiratory symptoms. **Methods:** Relevant studies were identified through a systematic search of the PubMed, Medline, Embase, Cochrane Library and Web of Science, and Scopus databases. The search terms included "nebulized heparin," "COVID-19," and "SARS-CoV-2." Studies that evaluated the use of nebulized heparin in COVID-19 patients with respiratory symptoms were included. The rest of the studies along with those that were not published in

English were excluded. The systematic review was registered under PROSPERO-CRD42023413927. **Observations:** Five studies have been included in this systematic review. Case reports, case series, observational studies, and randomized controlled trial (RCT) comprised the studies. The patient sample sizes ranged from 2 to 98. The studies assessed the efficacy of nebulized heparin in COVID-19 patients with variable disease severity. The evaluated outcomes included mortality, hospital stay duration, oxygen requirements, and laboratory parameters.

Conclusion: Based on the clinical studies included in this systematic review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in these patients. However, the studies had limitations, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness.

Keywords: Acute respiratory distress syndrome, Coronavirus disease-2019, Nebulized heparin, Pandemic, Randomized study, Randomized controlled trial, Respiratory failure, SARS, SARS-CoV-2, Unfractionated heparin.

Indian Journal of Critical Care Medicine (2023): 10.5005/jp-journals-10071-24511

HIGHLIGHTS

- This review integrates five clinical studies evaluating the efficacy of nebulized heparin in the treatment of coronavirus disease-2019 (COVID-19) pneumonia.
- In patients who received nebulized heparin, oxygen saturation was greater, inflammatory markers were lower, and hospital stays were short with no significant adverse effects.
- However, the studies had flaws, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups.

INTRODUCTION

Background

Patients having COVID-19-related acute respiratory distress syndrome (ARDS) are known to have high levels of coagulation parameters, including D-dimer, prothrombin time, and reduced platelet count.^{1,2} This leads to widespread endothelial dysfunction as well as microvascular and macrovascular pulmonary arterial thrombosis, which in turn leads to an increase in dead space and impairment of oxygenation even in the absence of reduced pulmonary compliance. Some of the specific pulmonary findings in severe disease include pulmonary fibrin deposits in the alveolar spaces as has been seen in postmortem studies and lung biopsies performed on COVID-19 patients with ARDS.^{3–5} Additionally, extensive pulmonary microvascular thrombi were observed in the arteries, small arteries, and arterioles of these patients. The

¹Department of Anaesthesia, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

²Department of Anaesthesia, Teerthanker Mahaveer Medical College, Moradabad, Uttar Pradesh, India

³Department of Anesthesia and Critical Care, Doon Medical College, Dehradun, Uttarakhand, India

⁴Department of CTVS, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Corresponding Author: Nidhi Gupta, Department of Anesthesia and Critical Care, Doon Medical College, Dehradun, Uttarakhand, India, Phone: +91 9760672721, e-mail: nidhigupta.doon@gmail.com

How to cite this article: Gupta B, Ahluwalia P, Gupta N, Gupta A. Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review. Indian J Crit Care Med 2023;27(8):572–579.

Source of support: Nil Conflict of interest: None

unique properties of unfractionated heparin include antiviral, anti-inflammatory, and anticoagulation which are relevant in SARS-CoV-2 infection.^{6,7} Nebulized unfractionated heparin (UFH) has been shown to have numerous positive effects in clinical studies. Nebulized UFH has an anticoagulant effect and the added advantage of being delivered locally to the lungs, targeting pulmonary fibrin deposition and inflammation. This type of administration is superior to intravenous administration because

[©] The Author(s). 2023 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



Fig. 1: PRISMA 2009 flow diagram

it allows for higher dosages, boosts local efficacy, lowers the risk of bleeding throughout the body, and is more effective overall.⁸⁻¹⁰ Importantly, previous research has shown that after nebulization, the levels of UFH in systemic circulation are not significant. This shows that it can be utilized along with systemic, therapeutic, or prophylactic anticoagulation without any concern for added impact on systemic anticoagulation.^{11,12}

Review Question: Can nebulized heparin therapy help improve the clinical outcome among COVID-19 patients with respiratory symptoms?

Objective: Our primary objective was to address our research question and find whether nebulized heparin has a role in improving outcomes in patients suffering from COVID-19 with respiratory symptoms. The primary objective was to assess patient improvement based on parameters, such as improved oxygenation, levels of inflammatory markers, shorter periods of mechanical ventilation, and a reduced length of hospitalization. The secondary objectives were to note any side effects with nebulization like bleeding and or derangement of coagulation parameters.

Methods

Search Strategy

A systematic search was made in the databases of PubMed, MEDLINE, EMBASE, Cochrane Library, Web of Science, and Scopus utilizing the keywords – "Heparin", "COVID-19", "COVID pneumonia" and "COVID ARDS", last search was completed on April 15, 2023. The systematic review was registered under PROSPERO-CRD42023413927. We thoroughly reviewed the abstracts and titles of studies to find information about the effectiveness and safety of nebulized heparin for patients with COVID-19 infections. However, we excluded studies involving pediatric patients, animal studies, and studies not published in the English language. Additional relevant publications were also identified from cross-references. We included adult patients, of any sex, ethnicity, having COVID-19 infection and presented with respiratory symptoms. The data collected in each study comprised the patient population, details of the intervention given (such as nebulized heparin dosage, frequency, timing, and duration), duration of ICU stay, mortality rates, length of mechanical ventilation, duration of ICU-free days, and safety endpoints (such as bleeding and coagulation parameters).

Study Selection

The titles and abstracts of the studies were screened for relevance by two reviewers, BG and NG. The eligibility of the full-text articles was then assessed based on the inclusion and exclusion criteria. Any disagreements were resolved through discussion with a third reviewer, PA.

Data Extraction

Data were collected from each study by utilizing a standardized form and inputting it into a Microsoft Excel spreadsheet (Microsoft Inc., USA), information such as the year and country of publication, study design, patient demographics, and patient outcomes was extracted. This included data on study and patient characteristics, intervention details, and outcome measures. However, statistical analysis for publication bias using a funnel plot and Egger's test was not conducted. The review follows the PRISMA guidelines for systematic review and meta-analysis and the Patient, Intervention Comparison, Outcome, (PICOS) Study Design was used to identify potential studies for inclusion (Tables 1 and 2).

Studies

For each intervention, reviews were given the highest priority, followed by randomized controlled trials (RCTs), observational studies, and lastly, case series and case reports were considered if no better evidence was available.

Risk of bias assessment: This was not done due to heterogeneity in the published data and limited RCTs.

Table 1: PICOS framework

Population	Adult patients with COVID-19 pulmonary disease
Interventions	Nebulized heparin
Controls	Normal saline
Outcomes	 Primary objectives: Improvement of oxygenation Inflammatory markers Patient outcome Mortality benefit Length of stay Duration of mechanical ventilation days
Study design	Randomized controlled trials Observational studies Case series

Table 2: The PRISMA guidelines for this systematic review

- 1. Identification
 - Database searching: PubMed, EMBASE, Cochrane Library, and Web of Science
 - Date of search: Till April 15th 2023
 - Keywords used: Nebulized heparin, COVID-19, SARS-CoV-2, and coronavirus
 - Language restriction: English
- 2. Screening
 - Titles and abstracts screened for relevance
 - Full-text articles assessed for eligibility
 - Any discrepancies resolved through discussion with a third reviewer
- 3. Eligibility
 - Inclusion criteria: Studies that assessed the role of nebulized heparin in COVID-19 patients
 - Exclusion criteria: Studies that did not report on nebulized heparin or COVID-19 patients
- 4. Included studies
 - Total number of studies included: 5
 - Study design: 1 randomized controlled trial, 4 observational studies
- 5. Data extraction
 - Data extracted using a standardized form
 - Extracted data included study characteristics, patient
 - characteristics, intervention details, and outcome measures
- 6. Data synthesis
 - Data synthesized narratively due to heterogeneity of studies

Data synthesis: The data were synthesized narratively, given the heterogeneity of the studies in terms of interventions, populations, and outcome measures.

REVIEW RESULTS

After applying the inclusion criteria, five studies were identified that met the eligibility requirements for this systematic review.^{13–18} Out of these, the majority were retrospective and observational, while only one study was a prospective, RCT. Demographic characteristics were similar in almost all the studies with the majority of patients

being males and more than 50 years of age. The patient sample sizes ranged from 2 to 98, involving a total of 246 COVID-19 patients (Table 3).

COVID-19 Patient Subsets

There was heterogeneity in COVID-19 patient symptomatology. While van Haren¹³ and DeNucci Gilberto¹⁵ took COVID-19 hospitalized patients, Gupta B et al.¹⁶ and Douen et al.¹⁷ incorporated mild-to-moderate category of COVID-19 patients, and Erelel M et al.¹⁴ studied COVID-19 patients with respiratory distress in their study (Table 4).

Dosage of Nebulized Heparin

There was heterogeneity in dosage, frequency, time to commencement, and duration of nebulized heparin therapy too in various studies. van Haren¹³ studied three different groups of dosage and frequency of nebulized UFH (5000 IU q8h, 10000 IU q4h, or 25000 IU q6h), Gupta B et al.¹⁶ used 10000 IU 6 hourly, Erelel M et al.¹⁴ 4000 IU 12h, DeNucci Gilberto,¹⁵ and Douen A et al.¹⁷ used 25000 IU q6h in their studies (Table 3).

28-day Mortality

According to van Haren et al.'s study, ¹³ 29.6% (29 out of 98 patients) of the overall cohort died while in the hospital. Meanwhile, In Gupta B et al.'s¹⁶ research, the mortality rate was 16.6%. However, the use of nebulized heparin did not affect mortality, which was instead linked to the severity of COVID-19 and the comorbidities of the patients. In DeNucci Gilberto et al.'s¹⁵ observational study, nebulized UFH resulted in lower mortality rates (15.8% or 6 out of 38 patients) than standard care (27% or 10 out of 37 patients), but the difference was not statistically significant. Douen A et al.¹⁷ found that the use of nebulized heparin provided a mortality benefit. (Table 4).

Length of Stay in Hospital/Time to Discharge

DeNucci Gilberto et al.¹⁵ patients who received nebulized UFH had a comparable time to discharge as those in the standard care group. van Haren et al.¹³ reported that survivors had a mean time to hospital discharge of 12.3 ± 9.4 days. Gupta B et al.,¹⁶ found that patients who were given nebulized heparin had a hospital stay duration of 19.43 ± 10.146 days (Table 4).

Mean PaO₂ or PaO₂/FiO₂

van Haren¹³ et al. reported improved oxygenation using WHO, MOCS score, and decreased FIO₂ over time in patients receiving high doses of nebulized heparin (25 000 IU q8h). Gupta B et al.¹⁶ reported significant improvement in oxygenation (pO₂/FIO₂ ratio) over 7 days (mean = 184.96, p = 0.00). Also, PaO₂ (84.17 ± 33.82) and SO₂ (92.30 ± 3.49) showed significant improvement. In a study conducted by Erelel M et al.¹⁴ it was observed that 75.8% of the patients in the Device Group who initially required complete oxygen support were able to breathe in "room air" without support on day 10 as compared with day 1. According to DeNucci Gilberto et al.¹⁵ the use of UFH resulted in lower mechanical ventilation rates in the mITT population (OR: 0.31; p = 0.08) (Table 4).

Coagulation and Hematological Factors Studied

van Haren et al.¹³ reported an increase in activated partial thromboplastin time (APTT) from 34 to 38 sec (insignificant). DeNucci Gilberto et al.¹⁵ found that there were no significant differences in APTT between the two treatment groups. Gupta

574

Table 3: Demo	graphic and	intervention	characteristics	of the studies

	51							
Authors	Type of study	N (total no. of patients)	Total no. of patients who received nebulized heparin	Type of study	Age- group	Male: female ratio	Heparin dose and frequency	Outcome parameters assessed
van Haren et al., ¹³ 2021	Multicenter case series (3)	98	98	Prospective observational case series	66 <u>±</u> 17 years	52%:48%	Nebulized UFH (5000 IU q8h, 10000 IU q4h, or 25000 IU q6h	APTT, SpO ₂ /FIO ₂
Gupta B et al., ¹⁶ 2023	Single center	30	30	Prospective observational study	Mean age 54.5	79%:21%	10000 U 6 hourly	pO ₂ /FIO ₂ ratio, LOS, mortality benefit
Mustafa et al., ¹⁴ 2021	Single center	80	40	Randomized controlled trial	60.02 ± 10.04	57%:43	4000 IU 12 h	Improvement in SpO ₂ , PaO ₂
DeNucci Gilberto et al., ¹⁵ 2023	Two centers	75	38	Randomized control study	51.95 ± 12.39	63%:27	25000 IU 6 h	Mortality, Length of hospital stay
Douen A et al., ¹⁷ 2021	Single center	3	3	Case reports	60.6	67%:27%	25000 IU 6 h	Mortality benefit

and team (16) reported that IL6 levels at day 7 were 59.09 \pm 110.45 compared with baseline levels of 62.85 \pm 101.52 after treatment. According to Erelel M et al.¹⁴ the control group showed significantly higher levels of C-reactive protein (CRP), while the Device Group had significantly higher levels of ferritin, leukocyte count, and neutrophil/lymphocyte ratio (all <0.01). However, there was no difference in D-dimer levels between the two groups (Table 4).

Adverse Outcomes

van Haren et al.¹³ reported that 16 patients (out of 98) had minor bleeding including epistaxis (n = 8), mouth bleeding (n = 2) and blood-tinged sputum (n = 5), and unspecified bleeding (n = 1). DeNucci Gilberto¹⁵ and Gupta B et al.¹⁶ reported no adverse outcomes with the usage of nebulized heparin (Table 4).

DISCUSSION

Nebulized medicines have been used in primary pulmonary disorders, such as asthma, chronic obstructive pulmonary disease (COPD), severe bronchopulmonary infections, colonized tracheobronchial tree as prophylaxis, or treatment of infection in cystic fibrosis patients for more than 20 years. These medicines include bronchodilators, antibiotics, mucolytics, and many other medicines. Because of its mucolytic properties, UFH has been successfully used in the treatment of cystic fibrosis patients without posing any safety concerns.^{18,19} Specifically, inhaled nebulized UFH has been used safely in patients who are already receiving systemic anticoagulation treatment. In acute lung injury and many other respiratory diseases, inhaled therapies have a time-tested and established role.²⁰ This is because the lungs have a large surface area, highly vascular parenchyma, and a large absorption capacity. This has resultant effects on COPD, asthma, and other bronchopulmonary diseases. Nebulized heparin has been successfully used in other modalities like burn injury.²¹ The bioavailability of heparin in the lungs and airways is significantly

enhanced by nebulization without any local and systemic bleeding.²² When nebulized UFH was used in other respiratory settings, there were no reported local side effects such as bleeding in the lung. In a study involving healthy volunteers, researchers investigated the effect of inhaled heparin on lung function and coagulation by administering a dose of 32000 IU of UFH to the lower respiratory tract. The study concluded that there was no impact on pulmonary function.²³ It was possible to demonstrate a dose-dependent anticoagulant effect on both the circulating blood (anti-factor Xa, APTT) and the endothelial cells as a release of tissue factor pathway inhibitor.²⁴ This effect was observed in the blood. When the receptor binding domain of the SARS-CoV-2 Spike S1 protein binds to UFH, it causes a change in shape that stops the virus from infecting human bronchial epithelial cells. The antiviral effect of UFH is significant and concentration-dependent, and threptic concentration is achieved by inhalation mode. Inhaled UFH reduces COVID-associated lung injury by reducing the deposition of fibrin, hyaline membrane formation, and prevention of microvascular thrombosis, due to its anticoagulation and anti-inflammatory properties. Nebulized heparin has been shown to improvise inflammation, oxygenation and pulmonary fibrin deposition in animal studies as well.^{5,25} Studies on humans are small, but they suggest that nebulized UFH reduces pulmonary fibrin deposition, slows down the advancement of acute lung injury, and accelerates the recovery process. In early-stage trials of patients suffering from acute lung injury and similar conditions, nebulized UFH improved lung injury, increased the duration of time without ventilator support, and reduced pulmonary dead space.²⁶

This review integrates five clinical studies evaluating the efficacy of nebulized heparin in the treatment of COVID-19 pneumonia.

In a study conducted by DeNucci Gilberto et al.¹⁵ the primary endpoint was the length of hospital stay (LOS) improvement. The study found that there was no significant difference in LOS between the group receiving heparin and the control group.

control group. D-dimer, and lymphocyte Respiratory server ent considered symptoms on as this was too short period day 1, were better to quantitatively account for
symptoms on symptoms on as this was too short period day 1, were better to quantitatively account for
day 1, were better to quantitatively account for
day 1, were better to quantitatively account for
in device aroup barametric changes
משל ז' אבוב מבוובו
day 1, were better to quantitatively account for
day 1, were better to quantitatively account for
day 1, were better to quantitatively account for
symptoms on as this was too short period day 1, were better to quantitatively account for
symptoms on as this was too short period day 1, were better to quantitatively account for
Respiratory Counts were not considered symptoms on as this was too short period day 1, were better to quantitatively account for
control group. U-uniter, and iyriphitocyte Respiratory Respiratory counts were not considered symptoms on as this was too short period day 1, were better to quantitatively account for
control group.D-dimer, and lymphocyteRespiratorycounts were not consideredsymptoms onas this was too short periodday 1, were betterto quantitatively account for
to be intubated in trial meant that CRP, ferritin, control group. D-dimer, and lymphocyte Respiratory counts were not considered symptoms on as this was too short period day 1, were better to quantitatively account for
to be intubated in the control group. Control group. Respiratory as this was too short period as this was too short period day 1, were better to quantitatively account for
three patients hadparameters after the 10-dayto be intubated intrial meant that CRP, ferritin,control group.D-dimer, and lymphocyteRespiratorysomptoms onsymptoms onas this was too short periodday 1, were betterto quantitatively account for
three patients hadparameters after the 10-daythree patients hadparameters after the 10-dayto be intubated incontrol group.control group.D-dimer, and lymphocyteRespiratorycounts were not consideredsymptoms onas this was too short periodday 1, were betterto quantitatively account for
intubations whereasChanges in the biochemical parameters after the 10-daythree patients hadthree patients hadthree patients hadparameters after the 10-dayto be intubated in control group.D-dimer, and lymphocyteRespiratorycontrol group.symptoms on day 1, were betterto quantitatively account for
supply or oxygen, no severe paraemic condutions. intubations whereas in the biochemical parameters after the 10-day three patients had the biochemical parameters after the 10-day to be intubated in control group. Dedimer, and lymphocyte Respiratory as this was too short period day 1, were better to quantitatively account for
Supply of oxygen, nosevere pandemic conditions.intubations whereaschanges in the biochemicalintubations whereaschanges in the biochemicalthree patients hadparameters after the 10-dayto be intubated inD-dimer, and lymphocyteRespiratorycontrol group.Respiratoryas this was too short periodday 1, were betterto quantitatively account for
ocyte, NL ratio category patients group required less group required less were nonrandomized due to supply of oxygen, no intubations whereas intubations whereas intubations whereas the severe parameters after the 10-day to be intubated in control group. Dedimer, and lymphocyte Respiratory as this was too short period day 1, were better to control or count for the
ocyte, NL ratio category patients group required less were nonrandomized due to supply of oxygen, no intubations supply of oxygen, no severe pandemic conditions. intubations intubations whereas Changes in the biochemical parameters after the 10-day trial meant that CRP, ferritin, control group. Respiratory control group. D-dimer, and lymphocyte as this was too short period day 1, were better
ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported The device and control groups bocyte, NL ratio category patients On admission 10 days group required less were nonrandomized due to supply of oxygen, no supply of oxygen, no severe pandemic conditions. Three patients had three patients had to be intubated in control group. Dedimer, and lymphocyte Respiratory symptoms on three better three patient had three patient had three herter here three herter here here
ferritin, CRP, octed not construct CND-19 severeOn admission10 daysNebulized heparin group required lessNone reportedThe device and control groupssupply of oxyte, NL ratiocategory patientsgroup required lesswere nonrandomized due tosupply of oxyte, NL ratiocategory patientsgroup required lesswere nonrandomized due tosupply of oxyte, NL ratiocategory patientscategory patientshe device and control groupssupply of oxytesupply of oxygen, nosevere pandemic conditions.changes in the biochemicalnitubations whereasthree patients hadthree patients hadtrial meant that CRP, ferritin,three patientscontrol group.RespiratoryD-dimer, and lymphocyteRespiratorysymptoms onsymptoms onsevere hours were not consideredday 1, were betterto quantitatively account for
ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported The device and control groups ocyte, NL ratio category patients or supply of oxygen, no intubations whereas three patients had to be intubated in control group. Dedimer, and lymphocyte symptoms on symptoms on three better here had a st his was too short period day 1, were better hour severe parter here had be counted by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had be a st his was too short period by the better here had by the better here had be a st his was too short period by a ccount for the better here had by the better here had be a st his was too short period by a ccount for the better here had by the better here here here here here here here
ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported vere and control groups coyte, NL ratio category patients or ategory patients or supply of oxygen, no intubations whereas three patients had three patients h
tay in days (m ± 5D) 19.43 ± 10.146 The device and control groups group required less supply of oxygen, no intubations whereas three patients had to be intubated in control group. Barameters after the 10-day three patients had to be intubated in control group. Respiratory symptoms on day 1, were better
crittin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported The device and control groups cyte, NL ratio category patients On admission 10 days Nebulized heparin None reported were nonrandomized due to severe pandemic conditions. cyte, NL ratio category patients On admission 10 days Nebulized heparin None reported The device and control groups cyte, NL ratio category patients 0n admission 10 days None reported The device and control groups control category patients 0n admission 10 days None reported The device and control groups control category patients None reported The device and control groups control category patients None reported The device and control groups control category patients Changes in the biochemical patients had Intubated in control control group. Control group. Control group. control group. Control group. Control were not considered symptoms on the patient of quantitatively account for the quantitatively account for
Ferritin, CRP, COVID-19 severe Duration of hospital stay in days (m ± SD) Ferritin, CRP, COVID-19 severe D0 admission ferritin, CRP, covID-19 severe 0n admission scyte, NL ratio category patients scyte, NL ratio category patients category patients none reported scyte, NL ratio category patients category patients none reported scyte, NL ratio category patients category patients severe pandemic conditions. intubations whereas three patients had three patients had trial meant that CRP, ferritin, control group. control group. Respiratory severe pandemic considered symptoms on as this was too short period day 1, were better to quantitatively account for
ferritin, CRP, COVID-19 severe On admission 10 days (m ± 5D) 19.43 ± 10.146 The device and control groups stay in days (m ± 5D) 19.43 ± 10.146 The device and control groups group required less supply of oxygen, no intubations whereas three patients had three patients had three p
10.54 10.54 deleterious effects Duration of hospital stay in days (m ± SD) Duration of hospital stay in days (m ± SD) deleterious effects Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin group required hes None reported Scyte, NL ratio category patients None reported The device and control groups Scyte, NL ratio category patients None reported were nonrandomized due to severe pandemic conditions. Scyte, NL ratio category patients None reported mere norrandomized due to severe pandemic conditions. Scyte, NL ratio category patients None reported mere norrandomized due to severe pandemic conditions. Action category patients None reported mere norrandomized due to severe pandemic conditions. Action the patients had three patients had three patients had Action the patients had to be intubated in control group. D-dimer, and lymphocyte Action the septiratory the severe not considered stips was too short period Action deleterion deleterion deleterion
In Early Large In Early Large In Early Large In Early Large In Early Large Duration of hospital In Early Large In Early Large In Early Large Duration of hospital Early In Early Large In Early Large In Early Large Duration of hospital Early In Early Large In Early Early Large In Early Large Do admission 10 days Nebulized heparin None reported In Early Large Do admission 10 days Nebulized heparin None reported In Early Early Large In Early Large COVID-19 severe On admission 10 days Nebulized heparin None reported In Early Earl
Image: Second
ferritin, CRP, COVID-19 severe On admission 10 days Mebulized heparin None reported the to screece particular of hospital stay in days (m ± 5D) 12.87 ± 0.54 belaterious effects 0.54 belaterions whereas 0.54 belaterions whereas 0.55 belaterions 0.55 belate
patients vertilation in days conclusions regarding efficacy (m ± SD) 12.87 ± (m ± SD) 12.87 ± conclusions regarding efficacy (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m ± SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m ± SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \mp SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \mp SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \mp SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12.87 ± (m \pm SD) 12
Ferritin, CRP, COVID-19 severe On admission 10 days conclusions regarding efficacy Ferritin, CRP, COVID-19 severe On admission 10 days more reported Socke, NL ratio category patients more reported stay in days (m ± SD) Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported Ferritin, CRP, COVID-19 severe Covid severe parteers Covid severe parteers Covid severe parten
Ter, PaO ₂ /FIO ₂ moderate category from mechanical succumbed to illness sample size too small to draw Patients ventilation in days ventilation in days conclusions regarding efficacy In ± SDI 12.87 ± In ± SDI 12.87 ± conclusions regarding efficacy In ± SDI 12.87 ± Duration of hospital stay in days conclusions regarding efficacy In ± SDI 12.87 ± Duration of hospital stay in days (m ± SD) potential infrequent In ± SDI 12.87 ± Duration of hospital stay in days (m ± SD) potential infrequent Stay in days Nebulized heparin None reported The device and control groups Stay in days None reported The device and control groups Stay in days None reported The device and control groups Stay in days None reported The device and control groups Stay in days Stay in days None reported the device and control groups Stay in days Stay in days None reported the device and control groups Stay in days Stay in days None reported there and control groups Stay in days Stay in days Stay in days there
Ther, PaO2/FIO3 moderate category from mechanical succumbed to illness sample size too small to draw ner, PaO2/FIO3 moderate category in ± 5D) 12.87 ± sample size too small to draw patients (m ± 5D) 12.87 ± 0.54 conclusions regarding efficacy (m ± 5D) 12.87 ± 10.54 conclusions regarding efficacy (m ± 5D) 12.87 ± 10.54 conclusions regarding efficacy (m ± 5D) 12.87 ± 10.54 conclusions regarding efficacy (m ± 5D) 12.87 ± 10.146 conclusions regarding efficacy (ferritin, CRP) COVID-19 severe On admission 10.146 (ferritin, CRP) COVID-19 severe Control group vere nonrandomized due to severe pandemic conditions. (ferritin, CRP) COVID-19 severe On admission 10 days None reported (ferritin, CRP) COVID-19 severe Conditions Changes in the biochemical (ferritin, CRP) cover pandemic conditions Control group vere pandemic conditions. (ferritin, CRP) cover pandemic conditions
An cauciny of the caregory and the caregory patients and the caregory patients and the caregory patients are caregory patients.
It ratio, IL6, COVID-19 midct-o- On admission 7 days Time to separate Five patients (16.6%) Absence of a control group, ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category indente category sample size too small to draw ner, PaO ₂ /FIO ₂ moderate category no admission 10.54 detectious effects ner, PaO ₂ /FIO ₂ COVID-19 severe On admission 10 days method size too sample of or order of order or
It ratio. IL6, ner, PaO2/FIO2 CoVID-19 mild-to- moderate category Tame to separate from mechanical wentilation in days Time to separate from mechanical wentilation in days Time to separate succumbed to illness Absence of a control group. ner, PaO2/FIO2 moderate category moderate category moderate category ample size too small to draw ner, PaO2/FIO2 moderate category moderate category moderate category ample size too small to draw refit notecate another category moderate category ample size too small to draw refit notecate another category moderate category ample size too small to draw refit notecate another category nothospital auccumbed to illness ample size too small to draw refit notecate another category nothospital auccumbed to illness ample size too small to draw refit notecategory nothospital succumbed to illness refital infrequent another category refit refit nothospital succumbed to illness refital metrial another category refit cov/te nothospital nothospital succumbed to inverse another categor
L ratio, Ll, COVD-19 mild-to- er, PaO ₂ /FlO ₂ moderate category and the separate five patients (16.6%) Absence of a control group, rentilation in days from enchanical succumbed to illness sample size too small to draw conclusions regarding efficacy (m ± SD) 12.87 ± 10.54 Absence of a control group, (m ± SD) 12.87 ± 10.54 Absence of a control group, (m ± SD) 12.87 ± 10.54 Absence of a control group, ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported in the elvice and control groups active intubations whereas intubations whereas intubations whereas intubated in control group, ferritin, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported in the biochemical three patients had three pat
- ratio, IL6, er, Pa0 ₂ FIO ₂ COVD-19 mild-to- moderate category On admission 7 days Time to separate five patients (16.6%) Absence of a control group. Absence of a control group. er, Pa0 ₂ FIO ₂ moderate category CoVD-19 mild-to- moderate category On admission 7 days Time to separate incumbed to illness Absence of a control group. erritin, CRP, erritin, CRP COVD-19 severe On admission 7 days Time to separate ind days (m ± SD) Absence of a control group. erritin, CRP, erritin, CRP COVD-19 severe On admission 10 days Nebulized heparin stay in days (m ± SD) Anone reportial infrequent deleterious effects erritin, CRP COVD-19 severe On admission 10 days Nebulized heparin stay in days (m ± SD) None reported erritin, CRP COVD-19 severe On admission 10 days None reported The device and control groups or potential infrequent deleterious effects erritin, CRP COVD-19 severe On admission 10 days None reported None reported erritin, CRP COVD-19 severe On admission 10 days None reported None reported erritin, CRP COVD-19 severe On admission 10 days None reported None reported erritin, CRP COVD-19 severe On admission None reported
ratio.ILG, COVID-19 mild-to- er, PaO ₂ /FIO ₂ moderate category er, PaO ₂ /FIO ₂ moderate category patients (16.6%) Absence of a control group. Moderate category attents (16.6%) Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.7 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.54 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.87 ± 10.146 Dr.51 (18.6 Absence of a control group. (m ± 5D) 12.81 ± 10.146 Absence of a control group. (m ± 5D) 12.81 ± 10.146 Absence of a control group. (m ± 5D) 12.81 ± 10.146 Absence of a control group. (m ± 5D) 12.81 ± 10.146 Absence of a control group. (m \pm 5D) 12.81 ± 10.146 Absence of a control group. (m \pm 5D) 12.81 ± 10.146 Absence of a control group. (m \pm 5
Latio, ILG, COVID-19 mild-to- er, Pa0,2/FIO2, moderate category er, Pa0,2/FIO2, moderate category patients (16.6%) Absence of a control group, from mechanical succumbed to illness as election bias ample size too small of aw ventilation in days (m ± SD) 12.87 ± 10.54 Duration of hospital stay in days (m ± SD) 19.33 ± 10.146 Luration category patients (16.6%) Absence of a control group, er, Pa0,2/FIO2, moderate category, conclusions regarding efficacy or potential infrequent 10.54 Duration of hospital stay in days (m ± SD) 19.33 ± 10.146 Firrith, CRP, COVID-19 severe On admission 10 days Nebulized heparin None reported The device and control groups group required less control groups cyte, NL ratio category patients On admission 10 days Nebulized heparin None reported The device and control groups cyte, NL ratio category patients On admission 10 days Nebulized heparin Constructions. The device and control groups control group. CovID-19 severe On admission 10 days Nebulized heparin Constructions. The device and control groups control group. CovID-19 severe Dandemic confitions. Advit, ratio category patients constructions. The device and control groups control group. CovID-19 severe partents had to be intubated in control group. CovID-19 severe partent had to be intubated in control group. CovID-19 severe partent had trian explained in control group. CovID-19 severe partent had trian explained in covID-19 severe par
Latio. ILG, COVID-19 mild-to- er, PaO ₂ /FIO ₂ moderate category er, PaO ₂ /FIO ₂ moderate category patients moderate patients moderate patients proper atterated at the lock-micula parameters after the lock-micula parameters afte
Latio, ILG, COVID-19 mild-to- ler, PaO ₂ /FIO ₂ moderate category er, PaO ₂ /FIO ₂ moderate category patients (166%) Absence of a control group. (m = 50) 12.87 ± (m mechanical succumbed to illness vertilation in days (m = 50) 12.87 ± (m = 50) 12.87 \pm (m = 50) 12.87 \pm (m = 50) 12.87 \pm (m
Latio,LL6, COVD-19 mild-to- er, Pao2,FIO2, moderate category etc, Pao2,FIO2, moderate category patients A condition in days patients A condition in days in 5SD 12.87 ± CovD-19 met or separate in 5SD 12.87 ± CovD-19 severe Conditions regarding efficacy in 45SD 12.87 ± CovD-19 severe CovD-19 severe Conditions regarding efficacy in 45SD 12.87 ± CovD-19 severe CovD-19 severe CovD-1
Latio, Iló, COVID-19 mild-to- er, PaO ₂ /FlO ₂ moderate category er, PaO ₂ /FlO ₂ moderate category patients P
Lratio, IL6, COVD-19 mild-to- ber, Pa0 ₂ /Fl0 ₂ moderate category er, Pa0 ₂ /Fl0 ₂ moderate category patients (m = 5D) 1287 ± starting this treatment veriliation in days (m = 5D) 1287 ± starting this treatment 0.54 buration of hospital starting this treatment 0.54 buration of hospital starting this treatment 0.54 buration of hospital starting this treatment 0.55 buration of hospital starting this treatment 0.54 buration of hospital starting this treatment or potential infrequent deleterious effects propregeting efficacy or potential infrequent deleterious effects breat patients breat or trong groups propregeting efficacy or potential infrequent or potential infrequent deleterious effects propregeting efficacy or potential infrequent deleterious effects propregeting efficacy propregeting efficacy p
Intration 16, France COVD-19 mid-to- benized UFH showed worsening oxygenation before suggests a selection bias Intration 16, France COVD-19 mid-to- moderate category On admission 7 days Time to separate the patients (16.6%) Absence of a control group. France Moderate category Time to separate the patients (16.6%) Absence of a control group. France Moderate category Time to separate the patients Five patients (16.6%) Absence of a control group. France Moderate category Time to separate the patients Time to separate the patients Absence of a control group. France Moderate category Time to separate the sector bias Time to separate the patients Absence of a control group. France COVD-19 severe On admission 10.54 Absence of a control group. Socyte. Nu admission 10 days Moherase Aeleterious effects. Socyte. On admission 10 days Moherase Condusions effects. Socyte. On admission 10 days Moherase Condusions effects. CovD-19 severe On admission 10 days Moherase Condusions effects. Socyte. COVD-19 severe
(n = 10) at the time patients who created inhaled of these events (n = 10) at the time patients who created inhaled worsening oxygenation before starting this treatment worsening worsening oxygenation before starting this treatment worsening worsening worsening worsening oxygenation before starting this treatment worsening worsenind worsening worsening worsening worsening wor
If ratio LI6, ratio LI6, coversition CovD-19 mild-to- bet Paloy/FIO2, moderate category On admission 7 days Time to separate from mechanical vertifiability Paleints who received inhaled worsening oxygenation before starting this treatment worsening oxygenation before male starting this treatment worsening oxygenation starting this treatment worken control groups worken and worken and wo
In a final of the final of
Intel (n = 3) or LMWH Also, the observation that (n = 10) at the time patients whon received inheld of these events of these events Intatio, IL6, COVD-19 mild-to- noderate category 7 days Time to separate net, PaO,FIO2, moderate category 7 days Time to separate noderate category 7 days Time to separate Eventhed to illness patients (n = 10) at the time patients succumbed to illness patients (n = 10) at the time sample size toos mall to daw patients (n = 20) 12.87 ± Ordusions regarding efficacy (n = 10) at the time succumbed to illness sample size toos mall to daw (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ± Drugion of hospital succumbed to illness (n = 20) 12.87 ±
Irato.ll6, COVID-19 mild-to- On admission 7 days Time to separate (in a log attent shore cevied inhaled or or senting oxygenation before starting this treatment suggers a selection bias Irato.ll6, COVID-19 mild-to- On admission 7 days Time to separate (in 6%) Asso, the ostervation that attent attent succumbed to illness or control groups extrato.ll6, COVID-19 mild-to- On admission 7 days Time to separate (in 6%) Asso, the ostervation before starting this treatment suggers a selection bias extrino table Moderate category 7 days Time to separate (in days (in ± 50) 12.87 ± Sample size too small to draw or not ligo traw
Latio, IL6, Er PaO2,FIO2, moderate category CoVD-19 mild-to- be lized UFH (n = 3) or LMWH (n = 10) at the time patients who received inheld of these events Also, the observation that patients who received inheld who received inheld patients Latio, IL6, moderate category COVD-19 mild-to- be lized UFH showed wentilation in days 7 days Time to separate time to separate Also, the observation that patients who received inheld wentilation in days er, PaO2,FIO2, moderate category On admission 7 days Time to separate Five patients (16.6%) Absence of a control group. stating this treatment wentilation in days er, PaO2,FIO2, moderate category Di admission 7 days Time to separate Five patients (16.6%) Absence of a control group. stating this treatment wentilation in days er, PaO2,FIO2, moderate category Di admission 7 days Absence of a control group. stating this treatment to detection seffects ferritn, CRP, erritn, CRP, covic. NL ratio COVD-19 severe a days (m ± 5D) 19.43 ± 10.146 Absence of a control group. control group. Absence of a control group. control group. ferritn, CRP, erritn, CRP, covic. NL ratio COVD-19 severe a days (m ± 5D) 19.43 ± 10.146 Absence of a control group. control group. Absence of a control group. control group. covic. All erritn, CRP, covic. All erritn, covic. All erritn None reported Absence of a control group. covic. All erritn
Lratio, IL6, ratio, IL6, corrented errente erre
Latio.IL6, Patients COVID-19 mild-to- be/iTed (IF) = 3) or LWWH (i = 10) at the time patients who received in the patients worsening oxygenation before patients No. the observation that in = 10) at the time patients No. the observation that patients Latio.IL6, Patients COVID-19 mild-to- bilized (IF) On admission 7 days Time to separate in = 10) at the time patients Patients No. the observation that patients Ler PaO.ZFIO, patients COVID-19 mild-to- patients On admission 7 days Time to separate in = 10) at the time patients Pasence of a control goups Rer PaO.ZFIO, patients COVID-19 mild-to- patients On admission 7 days Time to separate inclusions repeating efficacy (in ± 50) 12.87 ± Absence of a control goups Rer Titin, CRP, Sofe, NL ratio COVID-19 severe On admission 7 days Nebulized hepain None reported to patiential infrequent deleterious effects CoviD-19 severe On admission 10 days Nebulized hepain None reported The device and control groups CoviD-19 severe On admission 10 days None reported The device and control groups CoviD-19 severe On admission 10 days Nebulized hepain None reported The device and control groups CoviD-19 severe On ad
Image Control Time to servation that therapeutic doses of therapeutic dose therapeutic d
Lratio,Ll6, COVD-19 mild-to- moderate category On admission 7 days Five patients the patients who received imbaled of these events Non-the patients Lratio,Ll6, COVD-19 mild-to- moderate category On admission 7 days Time to separate from mechanical Five patients (16.6%) Also, the observation that patients Lratio,Ll6, COVD-19 mild-to- moderate category On admission 7 days Time to separate from mechanical Suggesta selection bias et Pla0_2,Fl02, moderate category On admission 7 days Time to separate from mechanical Suggesta selection bias et Pla0_2,Fl03, moderate category On admission 7 days Time to separate from mechanical Succombed to illness et Pla0_2,Fl03, moderate category No admission 7 days Succombed to illness et Pla0_2,Fl03, moderate category No admission Succombed to illness Suggesta selection bias et Pla0_2,Fl03, moderate category No admission Pla0_2,Fl03, Suster ed a cortrol group. et Pla0_2,Fl03, moderate category No admission Suster ed a cortrol group. Suster ed a cortrol group. et Pla0_2,Fl03, Evertine of editerio category patients
Lratio,LL6, COVD-19 mild-to- ere no concomitant Uratio,LL6, COVD-19 mild-to- ere Padoratic diffusion ere diffusion ere diffusion ere diffusion ere diffusion ere diffusion ere padoratic di diffusion ere padoratic diffusion ere padorat
Lratio.1L6, COVD-19 mild-to- mere on concomitant therapeutic doses of patients. Miloou to yage requirement therapeutic doses of patients. Miloou to yage requirement therapeutic doses of patients. Lratio.1L6, COVD-19 mild-to- moderate category On admission 7 days Time to separate to mechanically ventilated these events Paleo, the observation hat patients. Lratio.1L6, COVD-19 mild-to- moderate category On admission 7 days Time to separate to mechanical worsening oxygenation before worsening oxygenation before worsening oxygenation before worsening oxygenation before to moderate category ee, PaO_FFIO, On admission 7 days Time to separate worsening oxygenation before worsening oxygenation before worsening oxygenation before to mechanical worsening oxygenation before to mechanical worsening oxygenation before worsening oxygenation before worsening oxygenation before to mechanical worsening oxygenation before worsening oxygenation before to admission Lratio. COVD-19 severe On admission 10.54 Absence of a control groups cortex before and control groups or potential infrequentical stay in days (m ± SD) 13.81 ± 0.146 Absence of a control groups cortex before and control groups or potential infrequentical to deterto a deterto and control groups or potential infrequentical to deterto and control groups or potential infrequencial to deterto and control groups or potential infrequencial to deterto and control groups or potential information to deterto and control groups
Latio, LG, COVD-19 mild-to- ter Pao, ZHO, PAD, ZHO, Dia admission molecate category Zdays patients Fire patients (16.5%) patients Also, the observation that the observation that patients Latio, LG, COVD-19 mild-to- molecate category On admission Zdays Time to separate the patients (16.5%) Also, the observation that patients er, PaO, ZHO, Patients COVD-19 mild-to- molecate category On admission Zdays Time to separate the patients (16.5%) Absence of a control goup. er, PaO, ZHO, Patients COVD-19 mild-to- molecate category On admission Zdays Time to separate the patients (16.5%) Absence of a control goup. er, PaO, ZHO, Patients COVD-19 mild-to- molecate category patients On admission Zdays Absence of a control group. er, PaO, ZHO, Patients COVD-19 mild-to- molecate category On admission Zdays Absence of a control group. er, PaO, ZHO, Patients COVD-19 mild-to- molecate category On admission (16.0%) Absence of a control group. er, PaO, ZHO, Patients COVD-19 mild-to- molecate category On admission (16.0%) Absence of a control group. er, PaO, ZHO, Patients COVD-19 mild-to- patients On admission (16.0%) Absence of a control group. er, PaO, ZHO,
Internet Provotion Provotion Provotion Present Provotion Present Provotion Present Present Present Present Present Present Present Present Present Present Present Present
P < 0.001,
p < 0.001).
P < 0.001.)
Instruction
Lratio, IL5, COVD-19 mid-to- constant in = 1, All these: preterats except three without oxygen requirement threapeutic doses of threapeutic doses of threapeutic thre
Image in Slope,
Intain Integration On match from the product of th
Initiated UFH spottum (i.e.) cofinialed UFH spottum (i.e.) cofinialed UFH spottum (i.e.) mitted for COVID-19 P < 0.001).
Latio.LI6, COVD-19 mild-to- trange in slope, or inhaled UFH or slope, covD-19 disease was not or momental efform P < 0001,
Latio, Lls, COVD-19 mid-to- er, Paol, Andre J, And CoVD-19 disease without acygen requirement the rege on committant patients admitted for COVD-19 disease without acygen requirement the patients admitted for COVD-19 disease without acygen requirement the patients admitted for COVD-19 mid-to- er, Paol, Andre J, Mithese admitsory admitted for COVD-19 disease without acygen requirement the patients admitted for COVD-19 mid-to- er, Paol, Andre J, Mithese admitsory admitted for COVD-19 disease without acygen requirement the patients admitted for COVD-19 mid-to- patients admitted for COVD-19 mid-to- patients admitted for the sevents admitted for the sevents admitted for the admitted for the patients admitted for the admitted for the sevents admitted for the patients without acygen requirement aggregating admitted for the patients without acygen requirement aggregating admitted for the patients admitted for the admitted for the admitted for the admitted for the patients without admitted for the admitted for the admitted for the admitted for the patients with admitted for the admitted for the admitted for the admitted for the control group required the to admitted for the patients admitted for the admitted for the admitted for the admitted for the patients admitted for the admitted f
Latio, Lls, COVD-19 mild-to- Ratio, Latio, Lls, COVD-19 mild-to- Ratio, Rls, Ratio, Rls, Rls, Rls, Rls, Rls, Rls, Rls, Rls
Index in the intervention of the interventintervent of the intervention of the intervention of the interventi
International of the stand severity of of interlection and severity of interlection and severity of interlection and severity of interlection and severity of of interlection and severity and severity and
Latio Ll6, P = 0, num Oneerung and a severy of commencement (n = 2) and biod-riged duraton, and severy of cinnaled UFH aprum (n = 3), and a severy of cinnaled UFH aprum (n = 1), All these p < 0.001). If these p < 0.001. If a = 0, and commencement (n = 1, and p < 0.001. If a = 0, and commencement (n = 1, and p < 0.001. If a = 0, and respective doses of there events et. Po0, Fl0, p = 10) at the time p < 0.001. If a = 0, and there events et. Po0, Fl0, p = 10) at the time p < 0.001. If a = 0, and respective doses of there events et. Po0, Fl0, p = 10) at the time p < 0.001. If (n = 3) or LMM if a severy of respective doses of there events p < 0.001. If (n = 3) or LMM if a severy of respective doses of there events p < 0.001. If (n = 3) or LMM if a severy of respective doses of respective dose of respective doses of respective doses of respective dose of respective dose respective dose
Intaled UFH (= 8), model blechinged duration, and severity of of inhaled UFH (= 3), and blood-linged duration, and severity of of inhaled UFH P < 0001;
Intract of Res improved after the improved after the r=2) mouth bleeding of inhaled UH res im and producing res image of doses; method and of inhaled UH res ange of doses; method and res Inhaled UH res image of doses; method of inhaled UH res image of doses; method res image of doses; method res Inhaled UH res image of doses; method of inhaled UH res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res Inhaled UH res image of doses; method res image of doses; method res image of doses; method res image of doses; method res Inhaled Res image of doses; method res image of doses; method res image of doses; method res image of doses; method res Inhaled Res image of doses; method
Indumensations in the second under second un
Indicational Control Scale 3-5 ratio and the fub. retrement varia yer in a parter varia yer in the parter varia yer in a parter varia yer in the parter varia yer in the parter varia yer in the parter varia yer in a parter varia yer in the parter varia var
In al clinical scale 3-5 ratio and the FlO ₂ epistasis improved after HP ₁ representing angle of deses, methods and commercement in = 2), and blood-tinged diagram such and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and commercement in = 2), and seering of deses, methods and seering in store in a set of the seering and seering of the seering and seering or series and seering of the seering and seering or series and seering of the seering and seering or series and seering of the seering and seering or series and seering of the seering and seering or series and series and seering or series and seering or series and series and series and seeries and series and series and series and series and seeries and seeries and series and series and series and seeries and series and seeries and seeries and seeries and series and seeries and seeries and series and seeries and series and series and seeries and series and series and seeries and seeries and series and seeries and series and seeries and seeries and series and seeries and series and seeries and seeries and series and series and seeries and series and seeries and
Indictinical scale 3-5 atio and the FlO ₂ epistaxis The treatment was given in a common benefing and of obsess methods and common com
patents, mounteed out- natio and hF F(J), and clinical scale 3-5 mataon (hr, h), patents, mount bleefing) commencement proved after the commencement proved after the commencement proved after the patents, methods and commencement proved after the patents, and blood threed patents, and severy of patents, and blood threed patents, and severy of patents, and threed patents, and threed patents, proves after patents, and threed patents, patents, and threed patents, and threed patents, and threed patents, and threed patents, patents, and threed patents, and threed patents, patents, and threed patents, patents, and threed patents, and threed patents, patents, and threed patents, patents, patents, and threed patents, pa
patients, modified dot- and clinical scale 3-5 bieding including patients, modified dot- and clinical scale 3-5 bieding including patients, modified dot- patients, modified bleeding of mibaled UFH (n = 5), mouth bleeding of mibaled UFH showed were not concomitant of these events is of ubble of mibale screen of antified of these events is of ubble of mibale screen of antified of these events is of ubble of mibale screen of antified of these events is of ubble of mibale screen antified of these events is of ubble of mibales is of ubble of mibales is of ubble of mibales is of ubble is of ubble is of ubble of mibales is of ubble is of ub
match The relation activity of possibility of an adversity of possibility of adversity and poster in a severy of or impoved after the (n = 3) mouth breating angle of does, methods and or impoved after the (n = 3) mouth breating angle of does, methods and or impoved after the (n = 3) mouth breating angle of does, methods and or interface in the impoved and varied form of change in slope, (change in slope, (chang
aseline COVD-19 faceptialeid - 0.4.3.2.day The organ is patients had minor and severity of construction of the EQ, patients, month beefing and constrained and commencance improved file the (n = 2) and blood-tiged (does), methods and commencance improved file the (n = 2) and blood-tiged (does), methods and commencance in the commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does), methods and commencance (n = 2) and blood-tiged (does) and severity of (n = 1), these and severity of (n = 1), these and severity of (n = 1), the second (n = 1) and severity of (n = 1), the second
Description G ± 3 2 days The oxygen In experiment In the same comportion of graph of during and or diverse without a control graph of during and severity of and on direct scale severity of an on direct scale severity o
baseline Commentant Environment (intral scale 3 - 5) Eventson (intral scale 3 - 5) Eventson (intral scale 3 - 5) Eventson (intral scale 3 - 5) In al clinical scale 3 - 5) in al clinical scale 3 - 5) in al clinical scale 3 - 5) The oxygen (intral scale 3 - 5) Th oxygen (intral scale 3 - 5) The oxyg
Relet currents Tendent currents Predient currents Antent currents Imitations baseline COVD-19 hoppitalized - 6 + 3.1 days The exogent in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet in a miproved after the indication of the second accent was yet indit was
exercised Deficients condition of UH: Hreatment Itemication Imitations baseline CVID-19 hospitalized - 6 ± 3.12 days The oxygen The oxygen The second strain and the second strain and the second strain and second strain and the second strain and second
entities for leading of the fractions of Other activity of O
Time Internet I
Control Duration of tentraction Duration of tentraction Duration of tentraction Imitation baseline CVUP1 (spinet) of UHT returnent tentraction tentraction tentraction baseline CVUP1 (spinet) - 6 ± 3.1 days The oxygen 16 patients, had minor This as a retrospective case and and the FCIO, this and company This as a retrospective case and and the FCIO, this and company This as a retrospective case and a diversion of this and company This as a retrospective case and a diversion of this and company This as a retrospective case and a diversion of this and company This as a retrospective case and a diversion of this and company This as a retrospective case and a diversion of this and company baseline CVUD-19 hospinalized - 5 ± 3.1 days This this this this this this this this t
entities restrict tested Primetities of Hinterstructure Duration of Hinterstructure Diration structure Imitations structure Imitations structure reserve stead COVD-19 hospitalized patients, modified ordi- nations, modified ordi- and clinical scale 3-5 - 6 ± 3 12 days structure Merce acternes Imitations structure Imit

Table 4: Comparison of various parameters included in studies



Minimum of 1 h to a maximum of 1 h to a aximum of 1 h to a aximum of 1 h to a aximum of 1 h to an aximum of 27 h treatment benefit bleding, heparin- dinksion, with a mong patients induced the among patients is a status of the clinical care vs patients on administration of the progress of the trial and treated with nebulized UFH or any the open label status of the stands of care showed numerically lower in vaccination status through intubation. Nebulized UFH on top treatment arms showed numerically lower in the progress of the trial and intubation. Of care (10 out of 37 The were no patients; 27.0%), but significant this differences in APTT statistically significant the differences in APTT statistically significant the statustical difference and statustical differences and or care (10 out of 37 The wave and differences in APTT statistically significant the statustical differences and and of care standard of care standard of care standard of care standard and and and and and and and and and an	On admission Improved ventilator None reported Since this is a case report observation cannot be generalized, also there is ventilator-free days, decreased atelectasis, improved CO ₂ elimination, and reduced mortality Since this is a case report	ight heparin
Minimum of 1 h to a maximum of 27 h following hospital admission, with a median time of 4 h	On admission	eight heparin
COVID-19 hospitalized patients with WHO modified ordinal clinical scale (MOCS) score 3–5 scale and the score 3–5	COVID-19 moderate category with pneumonia	ime; LMWH, low-molecular-we
APTT(baseline and peak), heparin- induced thrombocytopenia	Chest X-ray	partial thromboplastin t
DeNucci Gilberto et al. ¹⁵ 2023	Douen A et al. ¹⁷ 2021	APTT, activated

However, subjects who received nebulized UFH had a similar time to discharge as the standard of care group. It is important to note that various factors, such as age, co-morbidities, and rate of recovery from COVID-19 can affect this outcome. In the rest of the studies, it varied from 12.3 \pm 9.4 days as reported by van Haren et al.¹³ to 19.43 \pm 10.146 days (Gupta B et al).¹⁶

Comparison of Mortality Outcome

van Haren et al.¹³ reported slightly high mortality in the overall cohort (29.6%). Though these patients were significantly sicker compared with survivors, had a significantly lower S/F ratio and higher FIO₂ (0.76 ± 0.25 vs 0.49 ± 0.31, p < .001) since the initiation of inhaled UFH. Gupta B¹⁶ noted the mortality rate as 16.6% owing to disease pathology and comorbidities. DeNucci Gilberto et al.¹⁵ found that mortality was numerically lower for nebulized UFH (6 out of 38 patients; 15.8%) vs standard of care (SOC) (10 out of 37 patients; 27.0%), but not statistically significant.

Improvement in Clinical Parameters – Oxygenation Status, Hemodynamics

van Haren et al.¹³ observed improved oxygenation using the WHO MOCS score and decreased requirement of FIO₂ over time in patients receiving high doses (25 000 IU q8h) in both intubated and nonintubated patients. It is important to note that the improvements observed could have happened on their own, without any external factors. Also, since there was no control group, we need to be careful when interpreting these findings. However, the fact that the study included a diverse range of doses, duration, and COVID-19 severity levels suggests that inhaled nebulized UFH is a safe option for COVID-19 treatment. Gupta B et al.¹⁶ also noted significant improvement in oxygenation $(pO_2/FIO_2 ratio)$ over 7 days (mean = 184.96, p = 0.00). Similarly, the improvement in PaO₂ (84.17 ± 33.82) and SO₂ (92.30 \pm 3.49) was significant as well. But this study was limited to the use of nebulized heparin in the i COVID pneumonia initial phase with mild-to-moderate ARDS. The absence of a control group and its small size was also a drawback. Erelel M et al.¹⁴ conducted a trial and classified patients with severe disease course as the "Device Group." Out of 33 patients in the Device Group who initially required complete oxygen support, 25 (75.8%) were able to breathe in "room air" without oxygen support by day 10 of the study. The reduction in oxygen requirement to correct hypoxemia in the Device Group was statistically significant compared with that of the control group (p < 0.01), hence the improvement was more homogenous and predictable. DeNucci Gilberto et al.¹⁵ reported that mechanical ventilation rates were lower with UFH in the mITT population (OR 0.31; p = 0.08).

Coagulation Effects/Derangements

None of the studies reported derangement of coagulation parameters such as APTT and D-dimer. According to a study by van Haren et al.¹³ patients who were not receiving therapeutic heparin infusion experienced a slight increase in their APTT when using nebulized UFH However, the increase, from 34 to 38 seconds was not clinically significant, as the peak value still fell within the normal APTT range. Meanwhile, patients who were receiving therapeutic heparin infusion experienced a nonsignificant increase in peak APTT when using inhaled nebulized UFH, although the sample size was limited to only three patients. Six patients missed a total of 25 doses of inhaled nebulized UFH due to epistaxis. Because of the presence of blood in the sputum of four patients, a total of 13 doses could not be administered. Epistaxis, blood-tinged sputum, and bleeding in the gastrointestinal tract, respectively, caused the inhaled nebulized UFH treatment to be discontinued in three patients (Table 4).

Heparin is available in a variety of delivery systems, including liquid dosage form, which can be injected, or inhaled via a nebulizer or a soft-mist inhaler, both of which are commercially available.

For maximum drug accumulation at the site of action and to provide an "enclosed system" to reduce contamination of environmental from saliva dispersion into the air, soft-mist inhaler technology was favored.²² As a result, healthcare workers and patients in a clinical setting faced a much lower risk of exposure to environmental contamination. The disposable nature of the soft-mist inhaler used in this study makes it ideal for use during a pandemic. Its mechanism makes it possible to fine-tune the dosage with each use. In this way, doctors would be able to tailor a treatment plan to the evolving needs of each patient. Erelel M et al.¹⁴ studied that following the application of nebulization, 57.08% of the droplets were concentrated over 3-5 stages of the impactor, with a cut-off diameter of 4.76–1.74 m. Fine particle fraction (FPF) was calculated to be 44.4%, mass median aerodynamic diameter (MMAD) was 5.37 m, and geometric standard deviation (GSD) was 1.63 m. A MMAD within a range of 1–5 m has been reported to aid in drug retention in the lower respiratory region. These findings suggest that the majority of the LMWH inhalation solution formed droplets that could get deposited in the bronchus and bronchiole region of the lung.

The majority of the studies found nebulized heparin safe which is consistence with published literature. In one study, several patients developed minor bleeding in the form of epistaxis and blood-stained sputum and two patients had major bleeding. These patients were also on therapeutic anticoagulation at the same time.

Limitations

Meta-analysis of outcome parameters was not done as there was heterogeneity in COVID-19 patients, also the outcome parameters were not uniform in various studies, nebulized heparin was also used in different dosages/formulations in various devices and variable duration of time. Limitations of individual studies are summarized in Table 4.

CONCLUSION

Based on the clinical studies included in this systematic review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in patients who received nebulized heparin, according to the published research. However, the studies had flaws, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness and more research into the effects and side effects of nebulized heparin in individuals with COVID-19 is required.

ORCID

Bhavna Gupta b https://orcid.org/0000-0002-3108-0408 Pallavi Ahluwalia b https://orcid.org/0000-0001-8730-3730



Nidhi Gupta https://orcid.org/0000-0001-7952-5317 *Anish Gupta* https://orcid.org/0000-0002-4704-6271

REFERENCES

- World Health Organization. COVID-19 clinical management: living guidance. https://www.who.int/publications/i/item/WHO-2019nCoV-clinical-2021-1. Accessed on: 20 April 2023.
- Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136(4):489–500. DOI: 10.1182/blood.2020006520.
- Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194:101–115. DOI: 10.1016/j. thromres.2020.06.029.
- Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of COVID-19. Am J Emerg Med 2021;39:213–218. DOI: 10.1016/j. ajem.2020.09.065.
- Bertanha M, Rodrigues LDS, Mellucci Filho PL, Moroz A, Pardini MIMC, Sobreira ML, etal. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: Triple-blind clinical trial. Medicine (Baltimore) 2021;100(51):e28288. DOI: 10.1097/MD.00000000028288.
- Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs, Pharmacol. Rev 2016;68(1):76–141. DOI: 10.1124/pr.115.011247.
- 7. Young, E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008;122(6):743–752. DOI: 10.1016/j. thromres.2006.10.026.
- Van Haren FMP, Page C, Laffey JG, Artigas A, Rimblas MC, Nunes Q, et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020;24(1):454. DOI: 10.1186/s13054-020-03148-2.
- Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Kidwai-Khan F, Skanderson M, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ 2021;372:n311. DOI: 10.1136/bmj.n311.
- Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–1231. DOI: 10.1007/ s00415-004-0519-8.
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5): 1094–1099. DOI: 10.1111/jth.14817.
- Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. Nebulized anticoagulants for acute lung injury – a systematic review of preclinical and clinical investigations. Crit Care 2012;12(16(2):R70. DOI: 10.1186/cc11325.
- 13. van Haren FMP, van Loon LM, Steins A, Smoot TL, Sas C, Staas S, et al. Inhaled nebulised unfractionated heparin for the treatment

of hospitalised patients with COVID-19: a multicentre case series of 98 patients. Br J Clin Pharmacol. 2022;88(6):2802–2813. DOI: 10.1111/ bcp.15212.

- 14. Erelel M, Kaskal M, Akbal-Dagistan O, Issever H, Dagistanli AS, Balkanci H, et al. Early effects of low molecular weight heparin therapy with soft-mist inhaler for COVID-19-induced hypoxemia: a phase IIb trial. Pharmaceutics 2021;13(11):1768. DOI: 10.3390/ pharmaceutics13111768.
- DeNucci G, Wilkinson T, Sverdloff C, Babadopulos T, Woodcock A, Shute J, et al. Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: a randomised controlled pilot study. Pulm Pharmacol Ther 2023;80:102212. DOI: 10.1016/j.pupt.2023.102212.
- Gupta B, Chandrakar S, Gupta N, Jain G. Nebulized heparin to reduce COVID-19-induced acute lung injury: a prospective observational study. Indian J Crit Care Med 2023;27(3):222–224. DOI: 10.5005/ jp-journals-10071-24420.
- 17. Douen A, Basit A, Panetti R, Farag P, Mbolu G, Popilevsky F, et al. Old medicine for new problems: potential role of a novel treatment using nebulized heparin in COVID-19 ARDS. Chest 2021;160(4):A943–A944. DOI: 10.1016/j.chest.2021.07.879.
- Phelps MK, Olson LM, Patel MAVB, Thompson MJ, Murphy CV. Nebulized heparin for adult patients with smoke inhalation injury: a review of the literature. J Pharm Technol 2020;36(4):130–140. DOI: 10.1177/8755122520925774.
- Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J 2006;27(2):354–358. DOI: 10.1183/09031936.06.00069005.
- 20. Miller AC, Elamin EM, Suffredini AF. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med 2014;42(2):413–419. DOI: 10.1097/ CCM.0b013e3182a645e5.
- 21. Xiaodong Lan, Zhiyong Huang, Ziming Tan, Zhenjia Huang, Dehuai Wang, Yuesheng Huang, Nebulized heparin for inhalation injury in burn patients: A systematic review and meta-analysis. Burns & Trauma 2020;8:tkaa015. DOI: 10.1093/burnst/tkaa015.
- 22. Yildiz-Pekoz A, Ozsoy Y. Inhaled heparin: therapeutic efficacy and recent formulations. J Aerosol Med Pulm Drug Deliv. 2017;30:143–156. DOI: 10.1089/jamp.2015.1273.
- Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 2002;19(4):606–610. DOI: 10.1183/09031936.02.00105202.
- Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–1755. DOI: 10.1111/jth.14828.
- 25. Ball L, Schultz MJ, Pelosi P. Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia. The Lancet. Respir Med. 2021;9(4):321–322. DOI: 10.1016/S2213-2600(20)30513-0.
- 26. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010:14(5):445. DOI: 10.1186/cc9269.